Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem Oct 28, 2024 08:15AM
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem Oct 8, 2024 08:15AM
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt Sep 24, 2024 08:15AM
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 Sep 20, 2024 08:15AM
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Sep 9, 2024 08:15AM